Current panorama and challenges for neoadjuvant cancer immunotherapy.

Current panorama and challenges for neoadjuvant cancer immunotherapy.

Publication date: May 20, 2020

Immune checkpoint inhibitors (ICI) may overcome cancer cells’ ability to evade the immune system and proliferate. The long-term benefit of ICI in the metastatic setting led to evaluate neoadjuvant ICI approaches in several tumor types such as melanoma, non-small cell lung cancer, and breast and bladder cancer. We summarize the current evidence for the efficacy of neoadjuvant ICI in cancer and discuss several unresolved challenges, including the role of adjuvant treatment after neoadjuvant ICI, the efficacy in oncogenic addicted tumors, and standardizing pathological assessment.

Concepts Keywords
Adjuvant Melanoma
Bladder Cancer Neoadjuvant therapy
Breast Oncology
ICI Cancer treatments
Immune System RTT
Immunotherapy Medicine
Lung Cancer Health
Melanoma Immunotherapy
Metastatic Tumors
Neoadjuvant Metastasis
Oncogenic Breast cancer
Tumor Lung cancer

Semantics

Type Source Name
disease MESH cancer
disease MESH melanoma
pathway KEGG Melanoma
disease MESH non-small cell lung cancer
pathway KEGG Non-small cell lung cancer
disease MESH bladder cancer
pathway KEGG Bladder cancer

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *